Boron-containing diacylhydrazine compounds

US9944659B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9944659-B2
Application numberUS-201514855646-A
CountryUS
Kind codeB2
Filing dateSep 16, 2015
Priority dateSep 17, 2014
Publication dateApr 17, 2018
Grant dateApr 17, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, R 4 , and R 5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound having Formula I: or a pharmaceutically acceptable salt, solvate, or boronic anhydride thereof, wherein: A is selected from the group consisting of hydrogen and —C(R 1 )(R 2 )(R 3 ); R 1 , R 2 , and R 3 are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; R 4 is selected from the group consisting of: X is selected from the group consisting of —O— and —N(R 8a )—; X 1 is selected from the group consisting of —O— and —N(R 8b )—; X 2 is selected from the group consisting of —O— and —N(R 8c )—; X 3 is selected from the group consisting of —O— and —N(R 8d )—; Y 1 is —(CR 9a R 9b ) m —; m is 0, 1, 2, or 3; Z 1 is selected from the group consisting of —O— and —N(R 8e )—, or Z 1 is absent; Z 2 is selected from the group consisting of O, S, and NH; R 6a is selected from the group consisting of hydrogen, —B(OH) 2 , and pinacolborane; R 6b , R 6c , and R 6d are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, hydroxy, amino, —N(H)CHO, —N(H)CN, —N(H)(cyano)alkyl, —CHO, optionally substituted alkyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, alkoxy, aryloxy, arylalkyloxy, alkylthio, heteroalkyl, carboxamido, sulfonamido, —COR 10 , —SO 2 R 11 , —N(R 12 )COR 13 , —N(R 12 )SO 2 R 14 or N(R 12 )C═N(R 15 )-amino; or R 6b is selected from the group consisting of hydrogen, halo, nitro, cyano, hydroxy, —N(H)CHO, —N(H)CN, amino, optionally substituted alkyl, haloalkyl, hydroxyalkyl, arylalkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, alkoxy, aryloxy, arylalkyloxy, alkylthio, heteroalkyl, carboxamido, sulfonamido, —COR 10 , —SO 2 R 11 , —N(R 12 )COR 13 , —N(R 12 )SO 2 R 14 or N(R 12 )C═N(R 15 )-amino; and/or R 6c and R 6d taken together with two adjacent carbon atoms form a fused optionally substituted cycloalkyl, optionally substituted heterocyclo, or optionally substituted heteroaryl group; R 6f is selected from the group consisting of hydrogen, alkyl, amino, alkylamino, dialkylamino, and hydroxy; R 7a , R 7b , R 7c , R 7d , R 7e , R 7f , R 7g , R 7h , R 7i , and R 7j are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, hydroxy, amino, optionally substituted alkyl, haloalkyl, hydroxyalkyl, alkoxy, and alkylthio; R 8a , R 8b , R 8c , R 8d , R 8e , R 8f , and R 8g are each independently selected from the group consisting of hydrogen, alkyl, optionally substituted aryl, optionally substituted heteroaryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl, and arylcarbonyl; R 9a and R 9b are each independently selected from the group consisting of hydrogen, alkyl, and cyano; R 5 is selected from the group consisting of: X 4 is selected from the group consisting of —O— and —N(R 8h )—; X 5 is selected from the group consisting of —O— and —N(R 8i )—; X 6 is selected from the group consisting of —O— and —N(R 8j )—; X 7 is selected from the group consisting of —O— and —N(R 8k )—; Y 2 is —(CR 9c R 9d ) n —; n is 0, 1 2, or 3; Z 3 is selected from the group consisting of —O— and —N(R 8l )—, or Z 3 is absent; Z 4 is selected from the group consisting of O, S, and NH; R 6e is selected from the group consisting of hydrogen, —B(OH) 2 , and pinacolborane; R 6g , R 6h , and R 6i are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, hydroxy, amino, —N(H)CHO, —N(H)CN, —N(H)(cyano)alkyl, —CHO, optionally substituted alkyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, arylalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, alkoxy, aryloxy, arylalkyloxy, alkylthio, heteroalkyl, carboxamido, sulfonamido, —COR 10 , —SO 2 R 11 , —N(R 12 )COR 13 , —N(R 12 )SO 2 R 14 or N(R 12 )C═N(R 15 )-amino; or R 6g is selected from the group consisting of hydrogen, halo, nitro, cyano, hydroxy, —N(H)CHO, —N(H)CN, amino, optionally substituted alkyl, haloalkyl, hydroxyalkyl, arylalkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, alkoxy, aryloxy, arylalkyloxy, alkylthio, heteroalkyl, carboxamido, sulfonamido, —COR 10 , —SO 2 R 11 , —N(R 12 )COR 13 , —N(R 12 )SO 2 R 14 or N(R 12 )C═N(R 15 )-amino; and/or R 6h and R 6i taken together with two adjacent carbon atoms form a fused optionally substituted cycloalkyl, optionally substituted heterocyclo, or optionally substituted heteroaryl group; R 6j is selected from the group consisting of hydrogen, alkyl, amino, and hydroxy; R 7k , R 7l , R 7m , R 7n , R 7o , R 7p , R 7q , R 7r , R 7s , and R 7t are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, hydroxy, amino, optionally substituted alkyl, haloalkyl, hydroxyalkyl, alkoxy, and alkylthio; R 8h , R 8i , R 8j , R 8k , R 8l , R 8m , and R 8n are each independently selected from the group consisting of hydrogen, alkyl, optionally substituted aryl, optionally substituted heteroaryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl, and arylcarbonyl; R 9c and R 9d are each independently selected from the group consisting of hydrogen, alkyl, and cyano; R 10 is selected from the group consisting of hydrogen, hydroxy, haloalkyl, hydroxyalkyl, arylalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, alkoxy, aryloxy, and arylalkyloxy; R 11 is selected from the group consisting of haloalkyl, hydroxyalkyl, arylalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl; R 12 is selected from the group consisting of hydrogen, haloalkyl, hydroxyalkyl, arylalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocycle, optionally substituted aryl, and optionally substituted heteroaryl; R 13 is selected from the group consisting of hydrogen, haloalkyl, hydroxyalkyl, arylalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, alkoxy, aryloxy, arylalkyloxy, and amino; R 14 is selected from the group consisting of haloalkyl,

Assignees

Inventors

Classifications

  • Drugs for disorders of the cardiovascular system · CPC title

  • Drugs for disorders of the blood or the extracellular fluid · CPC title

  • Antianaemics · CPC title

  • Immunosuppressants, e.g. drugs for graft rejection · CPC title

  • Ectoparasiticides, e.g. scabicides · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9944659B2 cover?
The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, R 4 , and R 5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus,…
Who is the assignee on this patent?
Intrexon Corp
What technology area does this patent fall under?
Primary CPC classification C07F5/025. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).